Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): THR-687

            Therapeutic Area: Ophthalmology Product Name: THR-687

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 25, 2021

            Details:

            Oxurion expecting to begin the Phase 2 development of THR-687 in DME in mid-2021 and are on-track to deliver the initial Part A data from the Phase 2 trial with THR-149 in DME later this year as planned.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): THR-149

            Therapeutic Area: Ophthalmology Product Name: THR-149

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 08, 2021

            Details:

            THR-149, Oxurion’s most advanced drug candidate, is being developed to potentially become the treatment of choice for the up to 40% of DME patients, who respond suboptimally to anti-VEGF therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): THR-149

            Therapeutic Area: Ophthalmology Product Name: THR-149

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2021

            Details:

            THR-149 is a potential first in class plasma kallikrein inhibitor with the possibility to become the treatment of choice for the 40% DME patients who respond sub-optimally to anti-VEGF therapy.